Research programme: chimeric antigen receptor T cell therapy - Celularity/Sorrento Therapeutics/TNK Therapeutics

Drug Profile

Research programme: chimeric antigen receptor T cell therapy - Celularity/Sorrento Therapeutics/TNK Therapeutics

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sorrento Therapeutics; TNK Therapeutics
  • Developer Celularity; Sorrento Therapeutics; TNK Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 05 Feb 2018 Sorrento Therapeutics intends to file an IND application with the US FDA in in first quarter of 2018
  • 05 Feb 2018 Sorrento Therapeutics plans a phase I trial in mid 2018
  • 05 Feb 2018 Preclinical trials in Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top